Acanthosis nigricans
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He mea noa ki te hunga momoto.
relevance score : -100.0%
ReferencesKo te Acanthosis nigricans he whakaaturanga kiri kiri o te āhua o raro. I te nuinga o te wā ka puta ki ngā kopa kiri pērā i te kaki, ngā kaokao, me te papa; he ōrite te āhua ki ngā papanga pouri me ngā tapa kore‑āhua. I te nuinga o te wā e hono ana tēnei āhuatanga ki te huka me te parenga o te insulin, engari, he ongo, ka tohu pea ki te pāpōkōkō i roto i te tinana. Ka puta pea nā te take o te homoni, nā te tango rongoā rānei, pērā i ngā steroids me ngā pire whakawhanau.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Ko te Acanthosis nigricans (AN) he mate kiri noa e hono ana ki ngā take hauora pērā i te parenga o te insulin, te mate huka, te momi, ētahi atu mate pūkū, raruraru homoni, me ngā tauhohenga ki ngā rongoā. Ko te maimoatanga AN e aro ana ki te whakatika i ngā raruraru hauora. I te timatanga, ka tirohia e ngā tākuta ngā tohu o te insulin resistance syndrome, pērā i te momona, te kolesterola teitei, te toto tiketike, me te mate huka momo 2. He maha ngā wā ka tohuhia e ngā tākuta ngā topical retinoids hei kōwhiringa maimoatanga tuatahi, ā, ka taea te awhina i te whakapawera o te kiri. Heoi, kāore pea rātou e tino whakatutuki i te pouri o te kiri. Ko ētahi atu momo maimoatanga (salicylic acid, podophyllin, urea, calcipotriol) e tonoa auau.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Te take
I te nuinga o te wā ka pā ki ngā tangata i raro i te 40 tau, he mea tuku iho pea ki te ira, ka pā ana ki te momona me ngā endocrinopathies, pērā i te hypothyroidism, te acromegaly, te polycystic ovary, te huka‑atete ki te insulin, te mate Cushing rānei.
○ Maimoatanga ― OTC Drugs
#40% urea cream